M2Bio Sciences has published its latest peer-reviewed research article on Psychedelics that has been released on the Nature Research platform (the first published paper can be found here).
“This is another great milestone for the company as the findings are very significant to psychedelic research. The research team led by Sanah M. Nkadimeng is making a lot of notable progress in bringing psychedelics to the forefront of medicine.” – CEO, Jeff Robinson.
The study investigates the effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushrooms use from genus Psilocybe and Panaeolus respectively, in pathological hypertrophy conditions in which endothelin-1 disorder is a contributor to pathogenesis.
Results proposed that the water extracts of Panaeolus cyanescens and Psilocybe cubensis did not aggravate the pathological hypertrophy induced by endothelin-1 and also protected against the TNF-α-induced injury and cell death in concentrations used.
Results support the medicinal safe use of mushrooms under controlled conditions and cautioned the use of higher concentrations.
The mounting evidence of psychedelic-assisted therapies in treating mental health disorders cannot be ignored anymore.
M2Bio Sciences is one of only a handful of companies that are legally allowed to research Psilocybin. Working under the radar with the premier scientific institutions of the Southern Hemisphere, M2Bio Sciences (OTC: $WUHN) has in little over two years accrued significant IP and research findings.
Full Disclosure: Jeff Robinson is the CEO, Dr.Anna Morera Leralta the CMO, and Luka Marjanovic is the Director of HR of M2Bio Sciences. Please feel free to contact Jeff via email at jeff@m2bio.co.
